Second quarter results met expectations with strong volume growth from improved mortality and operational execution. Revenue per treatment declined sequentially due to mix and policy changes, but full-year guidance was reaffirmed. Expanded HD therapies and capital initiatives support future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.